Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
Public ClinicalTrials.gov record NCT03897088. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tildrakizumab in the treatment of moderate to severe psoriasis of the scalp.
Study identification
- NCT ID
- NCT03897088
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 231 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 29, 2019 (Actual)
- Primary completion
- Feb 17, 2022 (Actual)
- Completion
- Feb 17, 2022 (Actual)
- Last update posted
- May 31, 2023
2019 – 2022
United States locations
- U.S. sites
- 19
- U.S. states
- 8
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| SPARC Site 18 | Encinitas | California | 92024 | — |
| SPARC Site 7 | Fountain Valley | California | 92708 | — |
| SPARC Site 3 | Fremont | California | 94538 | — |
| SPARC Site 12 | Huntington Beach | California | 92647 | — |
| SPARC Site 9 | Los Angeles | California | 90045 | — |
| SPARC Site 2 | Los Angeles | California | 90057 | — |
| SPARC Site 14 | Santa Monica | California | 90404 | — |
| SPARC Site 21 | Coral Gables | Florida | 33134 | — |
| SPARC Site 19 | Margate | Florida | 33063 | — |
| SPARC Site 5 | Sweetwater | Florida | 33172 | — |
| SPARC Site 13 | East Windsor | New Jersey | 08520 | — |
| SPARC Site 4 | Forest Hills | New York | 11375 | — |
| SPARC Site 16 | New York | New York | 10003 | — |
| SPARC Site 01 | Beachwood | Ohio | 44122 | — |
| SPARC Site 20 | Portland | Oregon | 97223 | — |
| SPARC Site 8 | Johnston | Rhode Island | 02919 | — |
| SPARC Site 17 | Cypress | Texas | 77433 | — |
| SPARC Site 11 | Houston | Texas | 77004 | — |
| SPARC Site 6 | Webster | Texas | 77598 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03897088, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 31, 2023 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03897088 live on ClinicalTrials.gov.